Voriconazole: Difference between revisions
imported>David E. Volk |
imported>David E. Volk mNo edit summary |
||
| Line 16: | Line 16: | ||
}} | }} | ||
'''Voriconazole''', sold under the brand name '''Vfend®''', is a | '''Voriconazole''', sold under the brand name '''Vfend®''', is a [[triazole]]-based antifungal drug used to treat infections due to [[fungus|fungi]], usually to treat invasive infection in immunocompromised patients or [[fluconazole]]-resistent strains. It is used to treat [[candidiasis]], [[apergillosis]], [[Scedosporium apiospermum]] and [[Fusarium]] species including [[Fusarium solani]]. | ||
== Mechanism of action == | == Mechanism of action == | ||
Revision as of 08:42, 17 May 2008
|
| |||||||
| voriconazole | |||||||
| |||||||
| Uses: | antifungal drug | ||||||
| Properties: | azole compound | ||||||
| Hazards: | see side effects & drug interactions | ||||||
| |||||||
Voriconazole, sold under the brand name Vfend®, is a triazole-based antifungal drug used to treat infections due to fungi, usually to treat invasive infection in immunocompromised patients or fluconazole-resistent strains. It is used to treat candidiasis, apergillosis, Scedosporium apiospermum and Fusarium species including Fusarium solani.
Mechanism of action
Azole-based antifungal agents, such as voriconazole, inhibit the cytochrome P450 enzyme 14-alpha-demethylase, and by doing so stop the conversion of lanosterol to ergosterol, an important component of fungal cell wall membranes. The lack of ergosterol makes the fungal cell wall permeable and inhibits cell growth.
Chemistry
The IUPAC name of voriconazole is (2R,3S)-2-(2,4-difluorophenyl)-3-(5-fluoropyrimidin-4-yl)-1-(1,2,4-triazol-1-yl)butan- 2-ol and its molecular formula, C16H14F3N5O, gives it a molecular mass of 349.3105 g/mol. The activity of the drug is based on the presence of an azole.
References & external links
- Voriconazole - FDA approved drug information (drug label) from DailyMed (U.S. National Library of Medicine).